ClinicalTrials.gg
RecruitingNCT06716580EQUALUpdated Nov 13, 2026

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

An interventional study of Circulating Tumor DNA (ctDNA) Assay in Lung Cancer and EGFR Gene Mutation, sponsored by Dana-Farber Cancer Institute. Recruiting at 6 sites in United States. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute — 7 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
Largest of 19
1,000 · median 33
Started
2025
with 1 other
No phase
10 of 25
4 open now
Registered
23rd of 25
by date

Among the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 23rd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

7 of the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.

The name of the test used in this research study is:

-Circulating free DNA (cfDNA) Assay

Read the detailed description

The goal of this research study is to evaluate the feasibility of a novel EGFR blood plasma ctDNA screening test among East Asian and Latinx participants at risk for lung cancer and ineligible for regular lung cancer screening. The test looks for a gene change called Epidermal Growth Factor Receptor (EGFR), specifically EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. This study seeks to determine if it is possible to use the blood test to detect this type of lung cancer that might not yet show symptoms.

The research study procedures include screening for eligibility, in-clinic visits, blood tests, and an optional questionnaire and/or focus group.

It is expected that about 1000 people will participate in the blood sample collection, 100 individuals in the survey, and 20 individuals in the focus groups.

03

Conditions studied

  • Lung Cancer
  • EGFR Gene Mutation

Browse trials for

Keywords

  • Lung Cancer
  • EGFR Gene Mutation
  • EGFR-related lung cancer
  • EGFR positive lung cancer
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Aims 1, 2, and 3)

Group 1 - Healthy Individuals (50-80 years of age):

Non-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.

Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.

Latinx/Hispanic includes those who self-identify as a person of Central or South American or Caribbean culture or origin.

Countries of origin include:

East Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.

Southeast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.

Latinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.

Group 2 - At-Risk Individuals (40-80 years of age):

Non-tobacco using (currently).

Individuals of any race or ethnicity who meet at least one of the following criteria:

Family history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled , or chronic bronchitis.

Symptoms of lung cancer for the past month, including unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.

Excluding individuals who concurrently present with a viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.

Additional Inclusion Criteria for Groups 1 and 2:

Aims 1 and 2: Able to complete and understand the study's in their preferred language.

Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:

Having had a chest CT scan in the last 12 months or having an anticipated chest CT scan during the enrollment period.

Having a current cancer or history of cancer within the last 3 years, excluding localized skin cancer, breast ductal carcinoma in situ, and localized prostate cancer.

Hemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.

Not able to comply with study requirements.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    ctDNA Assay

    All participants will be asked to provide blood samples and are administered a baseline questionnaire. The blood sample will be tested using the investigational ctDNA assay. If the investigational test is positive, these participants will be followed up by CLIA verification of results. A positive CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months. Participants will be notified of results. Additionally, participants may participant in optional studies: 1) One-time survey regarding perception of lung cancer screening and ctDNA testing, 2) Virtual focus group, 3) Blood banking study

    Device: Circulating Tumor DNA (ctDNA) Assay

Interventions

  • DeviceCirculating Tumor DNA (ctDNA) Assay

    Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.

06

What researchers measure

Primary outcomes

  1. Detection Rate of Non-Small Cell Lung Cancer

    The proportion of participants with a positive assay result who are subsequently diagnosed with lung cancer through clinical pathology, among all participants tested with the assay.

    Time frame: 2 years

Secondary outcomes

  1. Testing Turnaround Time

    The duration from the time of blood draw to the release of the ctDNA testing results to the study team.

    Time frame: Up to 2 years

  2. Recruitment Acceptability

    Determining proportion of screened patients who are eligible and who consent to the trial at each collaboration site

    Time frame: Up to 2 years

  3. Barriers to Sample Acquisition

    Examining barriers impeding scale-up of sample collection, handling, and delivery

    Time frame: Up to 2 years

07

Study locations

1 of 6 sites recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • Lecia Sequist, MD, MPH · Contactlvsequist@mgb.org · 617-726-5130
    • Lecia Sequist, MD, MPH · Principal investigator
  • Dana-Farber Cancer Institute at Steward St. Elizabeth's
    Brighton, Massachusetts 02135, United States
    Not yet recruiting
  • Dana-Farber Cancer Instiute Merrimack Valley
    Methuen, Massachusetts 01844, United States
    Not yet recruiting
  • Dana-Farber Cancer Institute South Shore
    South Weymouth, Massachusetts 02190, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 29 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
12 criteria edited, 8 added, 13 removed
What changed in the criteria
  • EditedInclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age):
  • AddedGroup 1 - Healthy Individuals (50-80 years of age):
  • EditedNon-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.
  • EditedSoutheast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.
  • EditedLatinx/Hispanic includes those who self-identify as a person of Central or South American and theor Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain.
  • AddedCountries of origin include:
  • AddedEast Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.
  • AddedSoutheast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.
  • AddedLatinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
  • AddedGroup 2 - At-Risk Individuals (40-80 years of age):
  • RemovedSelf-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
  • AddedIndividuals of any race or ethnicity who meet at least one of the following criteria:
  • EditedFamily history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled corticosteroids, or chronic bronchitis.
  • EditedSymptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.
  • EditedExcluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirusa viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.
  • RemovedAims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
  • RemovedAim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
  • AddedAdditional Inclusion Criteria for Groups 1 and 2:
  • EditedAims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdeantheir preferred language.
  • RemovedInclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age):
  • RemovedNon-tobacco using (currently)
  • RemovedSelf-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:
  • RemovedFamily history of EGFR positive LC L858R or exon 19
  • RemovedPersonal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
  • EditedHaving had a chest CT scan in the last 3 years12 months or having an anticipated chest CT scan during the enrollment period.
  • EditedHaving a current cancer or history of cancer within the last 53 years, excluding localized non-melanoma skin cancer and, breast ductal carcinoma in situ, and localized prostate cancer.
  • EditedHemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.
  • RemovedAdults unable to provide informed consent
  • RemovedIndividuals <40 years of age
  • RemovedPrisoners
  • RemovedPregnant women
  • RemovedPersonal diagnosis of lung cancer
  • EditedNot able to be compliantcomply with study requirements.
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 12 criteria edited, 8 added, 13 removed
    What changed in the criteria
    • EditedInclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age):
    • AddedGroup 1 - Healthy Individuals (50-80 years of age):
    • EditedNon-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.
    • EditedSoutheast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.
    • EditedLatinx/Hispanic includes those who self-identify as a person of Central or South American and theor Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain.
    • AddedCountries of origin include:
    • AddedEast Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.
    • AddedSoutheast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.
    • AddedLatinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
    • AddedGroup 2 - At-Risk Individuals (40-80 years of age):
    • RemovedSelf-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
    • AddedIndividuals of any race or ethnicity who meet at least one of the following criteria:
    • EditedFamily history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled corticosteroids, or chronic bronchitis.
    • EditedSymptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.
    • EditedExcluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirusa viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.
    • RemovedAims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
    • RemovedAim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.
    • AddedAdditional Inclusion Criteria for Groups 1 and 2:
    • EditedAims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdeantheir preferred language.
    • RemovedInclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age):
    • RemovedNon-tobacco using (currently)
    • RemovedSelf-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:
    • RemovedFamily history of EGFR positive LC L858R or exon 19
    • RemovedPersonal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
    • EditedHaving had a chest CT scan in the last 3 years12 months or having an anticipated chest CT scan during the enrollment period.
    • EditedHaving a current cancer or history of cancer within the last 53 years, excluding localized non-melanoma skin cancer and, breast ductal carcinoma in situ, and localized prostate cancer.
    • EditedHemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.
    • RemovedAdults unable to provide informed consent
    • RemovedIndividuals <40 years of age
    • RemovedPrisoners
    • RemovedPregnant women
    • RemovedPersonal diagnosis of lung cancer
    • EditedNot able to be compliantcomply with study requirements.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06716580
Responsible party
Narjust Florez (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Dec 4, 2024
Start date
Apr 1, 2025
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Fernando Pacheco
Contact
fernando_pacheco@dfci.harvard.edu
857-215-2794
Kylee Coonradt
Contact
kylee_coonradt@dfci.harvard.edu
617-582-8846
Narjust Florez, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion